Breaking News
Propranolol decreases the volume, color and elevation of infantile hemangiomas
Propranolol decreases the volume, color and elevation of infantile hemangiomas
A 6-month randomized, placebo-controlled trial of propranolol (2 mg/kg/day p.o. t.i.d.) was conducted in 40 children aged 9 weeks-5 years with facial or extrafacial infantile hemangiomas. Blinded volume measurements were conducted at weeks 0, 4, 8, 12, 16, 20 and 24 and blinded investigator scoring at weeks 0, 12 and 24. Hemangioma growth stopped at week 4 in the propranolol group and significant differences in the percentage volume change were seen between groups, maximally at week 12. Significant differences in hemangioma redness and elevation occurred in the propranolol group at weeks 12 and 24. No significant hypotension, hypoglycemia or bradycardia occurred, but one patient discontinued due to an upper respiratory tract infection. ...
Last updated: Tuesday, November 29, 2011
AccessDermatology | © Copyright 2011 Prous Science S.A.U. a Thomson Reuters business or its licensors.
All rights reserved. Legal Information. Send your comments to Webmaster
ISSN 2013-8202
This website is optimized for Explorer 7.0 and above, Firefox 3.0, Safari, and Chrome. Content remains viewable in older versions, but loss of formatting and design elements may occur.
This site complies with the HONcode standard for trustworthy health information:
verify here.